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Summary
BACKGROUND
  Oral contraceptives have been shown to be inversely associated with ovarian cancer. 
The interelation between use of other types of contraceptives and ovarian cancer have not 
been established. The objective of this narrative review was to examine epidemiologic studies 
of Intrauterine Contraceptive Devices (IUDs), long-acting progestogen-based contraceptives, 
partner vasectomy, and ovarian cancer.
METHODOLOGY
 
 Relevant epidemiologic studies were identified through a search for the MEDLINE, 
EMBASE and CINAHL databases. All studies published in English on March, 2018 were included.
RESULTS
  Of the 11 studies identified, two out of four reported statistically were significantly of lower 
risk for ovarian cancer associated with the use of Depot Medroxyprogesterone Acetate (DMPA). 
Whereas, two earlier studies observed statistically non-significant risk estimates greater than 
1.00. Eight studies assessing the association between ever-use of IUDs and ovarian cancer had 
mixed findings. A pair of double studies assessing the interelation between partner vasectomy and 
ovarian cancer reported statistically non-significant risk estimates below 1.00. 
CONCLUSION 
 Use of DMPA, levonorgestrel-releasing IUDs and partner vasectomy's association is of 
lower risk of ovarian cancer. The Association of Ovarian Cancer with use of IUDs only is not clear.
However, copper- bearing IUDs possibly increase a risk. These findings are not definitive; more 
studies are needed to assess these associations more.
Key words: “Ovarian cancer, DMPA, Vasectomy, IUDs, Contraceptives”.
 
Introduction
 Ovarian cancer continues to be a devastating 
disease despite advances in treatment. This is mainly 
because it is usually detected at an advanced stage (70% 
diagnosed at stage III) [1]. 
 Reproductive factors had been shown to have 
a substantial influence on the risk of this disease. 
Of particular interest are contraceptives, as those, 
if causally associated with reduced risk, provide an 
[Afr. J. Health Sci. 2019 32(5) : 6 - 17 ]
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approach to prevention that was within an individual’s 
control. In addition, because contraceptives are widely 
used, even a small variation in risk would have far 
reaching consequences for public health [2].
 Oral Contraceptives (OCs) have been shown 
to be inversely associated with ovarian cancer ever-use 
of OCs was associated with a 30-40% lower risk than 
never-use. If considered causal as seems reasonable 
given both the consistency of the epidemiologic data 
and the plausibility of the likely mechanisms,  then we 
can say that protection is greater with longer duration 
of use, with about 20% reduction in risk factor after 5 
years of use, increasing to 50% or more after 15 years of 
use [3 - 7]. 
 This protective effect declines with time since 
last use.  A similar beneficial effect is seen in BRCA 
mutation carriers and in women with a family history of 
ovarian cancer, albeit from a higher baseline risk. Other 
factors known to be associated with a lower risk of 
ovarian cancer include parity, breastfeeding, and tubal 
ligation [5 - 8].
 The association between use of other types of 
contraceptives and the risk of ovarian cancer has not 
been established. Because the mechanisms of action of 
OCs on ovarian cancer are not fully established, asking 
whether other approaches to contraceptives provide 
benefit is an important question. Here we present a 
narrative review of epidemiologic studies addressing the 
relationship between the risk of ovarian cancer and the 
use of intrauterine contraceptive devices (IUDs), long-
acting progestogen-based contraceptives, and spousal/
partner vasectomy.
Materials and Methodology
 Relevant epidemiologic studies were identified 
through a research of the MEDLINE, EMBASE and 
CINAHL database using the key words (‘ovarian 
cancer’/‘ovarian tumour’) and (‘injectable contraceptive 
agent’/ ‘medroxyprogesterone acetate’ /‘contraceptive 
implant’) and (‘intrauterine contraceptive device’/
intrauterine contracept*’) ‘vasectomy’ and ‘cancer risk’. 
 All original studies published in English on 
20th March, 2018 were included. Additional papers 
were found by checking reference lists. No eligibility 
criteria was used based on quality of individual studies. 
Alternatively, study quality was assessed, with relevant 
comments included in the text and Tables next. pg.
A total of 11 articles were identified. Of which:
1. Four studies assessed the association of ovarian 
cancer and use of Depot Medroxy Progesterone 
Acetate (DMPA). 
2. Eight reported on the association with the use of 
IUDs.
3. Two examined the association with partner 
vasectomy (some studies investigated more than 




 Whether there was an association between 
progestogen-based, long-acting contraceptives and the 
risk of ovarian cancer, which DMPA has been most 
studied, no establishement had been made. Study 
summary assessing the relationship between use of 
DMPA, and the risk of ovarian cancer is presented in 
Table 1. next page.
 In a study in Shanghai involving 229 women 
with ovarian cancer and a similar number of controls, 
there was no statistically significant association between 
DMPA and ovarian cancer: compared to never-use, ever-
use of DMPA  associated with an odds ratio (OR) of 2.8 
(95% confidence interval [CI]: 0.9, 8.5). There was no 
relationship between duration of DMPA use and the risk 
of ovarian cancer.
 However, only a small number (24 cases and 6 
controls) of participants had used DMPA. In addition, in 
this study, contrary to what is otherwise well established, 
an inverse association between OCs and ovarian cancer 
was not found (OR = 1.8; 95% CI: 0.8, 4.1, confined to 
short duration users [<1 year]) [9]. 
 The WHO Collaborative Study of Neoplasia 
and Steroid Contraceptives, conducted in Mexico and 
Thailand, found no association between DMPA use and 
ovarian cancer. There was also no relationship between 
ovarian cancer and patterns of use of DMPA (duration 
of use; time since first use). Ever-use of DMPA was 
associated with a relative risk (RR) of 1.07 (95% CI: 0.6, 
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1.8). Although there was a difference in the direction 
of association between histologically borderline and 
malignant tumours among histological subtypes, the 
differences were not statistically significant. 
 However, the study had low statistical power 
to detect an interelation between DMPA use and 
epithelial ovarian cancer. (23% chance of detecting a 
25% risk reduction of Epithelial Pvarian Cancer(EOC), 
at a statistical significance level of 0.05, in ever-users of 
DMPA, and much lower power to detect an association 
with duration of use) [10].
 Two recent, large studies have found DMPA 
to be inversely associated with ovarian cancer, with 
evidence of a dose-response relationship with longer 
duration of use. 
 In a large hospital-based case-control study 
involving South African black women, compared to 
never-use of hormonal contraceptives, ever-use of 
injectable contraceptives was found to be inversely 
associated with the risk of ovarian cancer (OR = 
0.35; 95% CI: 0.17, 0.71). Exclusive use of injectable 
contraceptives for ≥5 years was also associated with a 
statistically significant lower risk (OR = 0.07; 95% CI: 
0.01, 0.49); 
 However, it was  noted that the association 
with long duration use was based only on one case. In 
addition, in this study, injectable contraceptives were 
assumed to be progesterone-only preparations, but use 
of combined injectable contraceptives in this group of 
women cannot be ruled out [3].
 A more recent hospital-based case-control study 
carried out in Thailand found a statistically significant 
lower risk in ever-users compared to never-users of 
DMPA (OR = 0.61; 95% CI: 0.44, 0.85). An inverse 
trend in risk was observed with longer duration of use, 
with a statistically significant lower risk being observed 
after more than 3 years of use (OR = 0.17; 95% CI: 0.07, 
0.39). So far, this is the largest case-control study done 




 Studies have produced conflicting results 
regarding the use of IUDs and ovarian cancer. A 
summary of studies assessing the relationship between 
use of IUDs, and the risk of ovarian cancer is presented 
in Table 2 next page. 
 In the Shanghai, case-control study, compared 
to never-use, ever-use of an IUD was linked with a 
possibly lower risk of ovarian cancer (OR = 0.5; 95% 
CI: 0.2, 1.1), but the study had low statistical power [9].
 A prospective cohort study (the Shanghai 
Women’s Health Study [SWHS]), reported no 
association between risk of ovarian cancer and use of 
IUDs (hazard ratio [HR] = 1.03; 95% CI: 0.62, 1.73, for 
ever-use compared to never-use). 
 Overall, no conection was found between 
use of any contraceptive method and ovarian cancer 
including oral contraceptive use and tubal ligation, 
(HR = 1.10; 95% CI: 0.66, 1.82 and HR = 1.17; 95% 
CI: 0.62, 2.20, respectively). This study had a small 
number of cases and the sample size and power were 
probably inadequate to assess the association between 
intrauterine contraceptive use and ovarian cancer 
(power and sample size calculations were not provided). 
In addition, information was not available on the type of 
IUDs or OCs used [11]. 
 After a longer follow up (mean follow-up of 
12.6 years), compared to never-use, ever-use of IUDs 
was not associated with a statistically significant lower 
risk of ovarian cancer (HR=0.79; 95% CI: 0.55, 1.13). 
However, relative to never use, use for >20 years was 
inversely associated with ovarian cancer (HR=0.62; 
95% CI: 0.40, 0.97). A dose-duration response was also 
observed (P-trend = 0.04). 
 There was no difference in risk between serous 
and non-serous tumours. No association was observed 
between use of oral contraceptives or tubal ligation and 
ovarian cancer (HR = 1.02; 95% CI: 0.69, 1.51 and HR = 
0.96; 95% CI: 0.60, 1.56, respectively) [12].
 A hospital-based case-control study in Vietnam 
reported a statistically significant lower risk of ovarian 
cancer in ever-users of IUDs (OR=0.5; 95% CI: 0.4, 0.8). 
In this study, the relationship between risk and duration 
of use was not described, and type of IUDs used was not 
specified. More so, use of OCs was not associated with 
ovarian cancer (OR=0.8; 95% CI: 0.4, 1.6) [13].
 Ness et al. also observed a statistically significant 
lower risk of ovarian cancer with IUD use (OR = 0.75; 
95% CI: 0.59, 0.95).  In this study, IUDs were inversely 
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associated with ovarian cancer among those with short 
duration of use (OR = 0.53; 95% CI: 0.39, 0.72 for use for 
≤4 years), but there was a statistically non-significant 
positive association with prolonged use (OR = 1.11; 95% 
CI: 0.63, 1.96 and OR = 1.40; 95% CI: 0.82, 2.39, for use 
for 5-9 years and ≥10 years respectively). 
 It is instructive to note that only a small number 
of participants (n = 14) had used the progestin-containing 
IUD, which may not have the same association as the 
copper-bearing IUDs. In this population-based case-
control study, all the contraceptive methods assessed 
were found to be inversely associated with ovarian 
cancer [4].
 In contrast, the US Nurses’ Health Study 
reported a significant higher risk of ovarian 
cancer for ever-users of IUDs compared with 
never-users (RR = 1.76, 95% CI: 1.08, 2.85), 
with the association being stronger for serous and 
endometrioid histological subtypes: RR = 2.17 and 
RR = 2.40 respectively (95% confidence intervals 
for these relative risks were not provided). 
 In this study, the relationship between risk 
and duration of use was not reported. In addition, 
the IUDs used by participants in this study were 
mainly the copper-bearing type and may not 
reflect the association (if present) with the newer 
levonorgestrel-releasing IUDs (LNG-IUS) [5].
 An inverse association specifically between 
use of LNG-IUS and ovarian cancer has been 
reported. In a large cohort study in Finland that 
involved 93,843 women (1,083,126 women-years), 
use of LNG-IUS for the treatment of menorrhagia 
was associated with a lower risk of both invasive and 
borderline ovarian cancer (standardised incidence 
ratio [SIR] = 0.59; 95% CI: 0.47, 0.73 and SIR = 
0.76; 95% CI: 0.57, 0.99, respectively). 
 Among invasive tumours, the inverse 
association was strongest for Mucinous Carcinoma 
(SIR = 0.49; 95% CI: 0.24, 0.87) and weakest for 
Serous Carcinoma (SIR = 0.75; 95% CI: 0.55, 0.99), 
although differences in risk between histologic 
types were not statistically significant [14]. 
 A lower risk for ovarian cancer (SIR = 0.60; 
95% CI: 0.45, 0.76 for invasive and SIR = 0.76; 
95% CI: 0.54, 1.03 for borderline tumours) was 
reported after a shorter follow-up in the same study 
(855, 324 women years) [15]. 
 However, these risk estimates were not 
adjusted for possible confounders including parity, 
and use of OCs. Use of LNG-IUS by the reference 
population or history of Oophorectomy could not 
be ruled out. 
 
 Furthermore, the findings of this study may 
not be generalizable because participants were on 
treatment for menorrhagia therefore, their risk for 
ovarian cancer may differ from that of the general 
population.
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Vasectomy
There have been only two 
studies of the association 
between partner vasectomy 
and ovarian cancer. The 
US Nurses’ Health Study, 
a prospective cohort study, 
found no association between 
spousal vasectomy and ovarian 
cancer (RR = 0.87; 95% 
CI: 0.63, 1.19) [5], whereas 
a population-based case-
control study found an inverse 
association of borderline 
statistical significance with 
vasectomy (OR = 0.7; 95% CI: 
0.61, 0.99) [4]. A summary of 







































































































































































































































































































































































































































































































































































































































































































































































African Journal of Health Sciences  Volume 32, Issue No. 5, September - October  201914
Discussion
 In contrast to the inverse associations found 
recently, large studies on DMPA use and ovarian 
cancer,  findings of the earlier studies on the same risk 
are surprising. This is because the biologic effects of 
DMPA could be expected to be protective. Inspide of 
, the low number of participants in these studies and 
the fact that DMPA had been used only for a short time 
made it hard to have strong confidence in the results of 
these studies [6].
 Several hypotheses to explain the inverse 
association between OCs and ovarian cancer that had 
been suggested include:
 (i)    Inhibition of ovulation 
 (ii)   Suppression of endogenous gonadotropin
 (iii)  Androgen and oestrogen production 
 (iv)   Increased levels of circulatory progesterone
 Long-acting progesterone-based contraceptives 
exert effects similar to those suggested to be responsible 
for the protective effect of OCs. Most importantly, these 
contraceptives inhibit ovulation. Use of DMPA also 
leads to a decrease in plasma oestrogen to levels similar 
to that found in the early to mid-follicular period (100pg/
ml) [16,17, 18, 19].
 Lower levels, similar to post-menopausal levels 
(100pmol), had been reported in users experiencing 
amenorrhoea. Although DMPA inhibits endogenous 
progesterone production use of DMPA results in high 
levels of plasma progesterone (1ng/ml) for the 3 months 
following injection  DMPA inhibited the mid-cycle LH 
surge but, overall, did not affect gonadotropin levels 
 From the above, the overall effect should 
be a reduced risk of ovarian cancer if, indeed OCs 
confer protection through these proposed biologic 
mechanisms.[3, 17].
 On the other hand, it had been suggested 
that DMPA might not have had the same effect as the 
progestin components of OCs because they did not belong 
to the same class of progestins. Most of the progestins 
in combined OCs were 19-nortestosterone derivatives, 
whereas DMPA was a progesterone derivative [18]. 
 It had also been suggested that DMPA might 
have an androgenic effect, which could thus, increase 
the risk of ovarian cancer [20].
 Differences in associations between long-term 
and short-term use of IUDs were reported. The higher 
risk with longer duration of use had been attributed to 
the fact that IUDs require replacement every 5 to 10 
years, thus, longer use means more replacements. That 
can increase the risk of upper-genital-tract infections. 
 In contrast, the lower risk associated with short-
term use may be explained by the spermicidal effect 
of IUDs, thus reducing local inflammation, or use of 
the newer levonorgesterel-releasing IUDs (LNG-IUS), 
which might have been associated with lower risks of 
ovarian cancer. 
 Use of IUDs was thought to increase the risk 
of infection and inflammation in the peritoneal cavity, 
which might lead to a higher risk of ovarian cancer 
[4, 5]. Chronic inflammation, including sub-clinical 
inflammation, had been shown to increase the risk of 
cancer in affected organs [21-23]. 
 Consistent with the inflammatory hypothesis 
in ovarian carcinogenesis was the observed lower risk 
with prolonged use of low-dose aspirin, and other non-
steroidal anti-inflammatory agents [19, 24]. Exposure to 
inflammatory factors such as asbestos and talc had been 
linked to ovarian cancer although available evidence 
was inconclusive. The inflammatory hypothesis was 
also supported by the higher risk of ovarian cancer in 
women with endometriosis [19, 25, 26]. 
 Pending further evidence and considering 
the hypotheses of ovarian carcinogenesis, whereas 
levonorgestrel - releasing IUDs (LNG - IUS) were 
associated with lower risk as were other long-acting 
progestogen - based contraceptives, copper - bearing 
IUDs (Cu - IUDs), that cause inflammatory reaction, 
were less likely to be protective and could increase risks.
      The relationship between spousal / partner 
vasectomy and the risk of ovarian cancer was the 
least studied. Available evidence pointed towards no 
association or an inverse association. How and why 
vasectomy might modify the risk of ovarian cancer have 
not been determined. From the proposed theories of the 
pathogenesis of ovarian cancer, the following biological 
mechanisms were worthy of consideration.
 The constituents of semen, might have the 
potential to cause inflammation, partly gain access to 
the upper genital tract via facilitation by spermatozoa. 
Spermatozoa have the ability to bind most of the seminal 
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constituents. Infectious agents from the lower genital 
tract are thought to be responsible for upper genital tract 
infection [28]. 
 Spermatozoa have been proposed as one of the 
factors that facilitate the ascent of bacteria from the lower 
to the upper genital tract [29]. Following deposition of 
spermatozoa into the female genital tract, other than the 
single spermatozoa that fertilizes the ovum, all undergo 
degeneration [30]. 
 Therefore, in the absence of spermatozoa, 
a lower risk of infection and inflammation could be 
predicted and, thus, lowering risk of ovarian cancer. 
Vasectomy results in the reduction of seminal plasma 
content of dihydrotestosterone and Testosterone In 
addition, the absence of spermatozoa, which usually bind 
hormones in semen - including  Testosterone, follicle 
stimulating hormone (FSH), luteinizing hormone (LH), 
and oestrogen - could lower the risk because of the lower 
levels of these hormones in the upper genital tract [27, 
31].
 A reduction in seminal constituents of prostatic 
origin following vasectomy was demonstrated. That 
include; the polyamines (spermine and spermidine). 
Oxidation products of polyamines could have a similar 
effect on risk of ovarian cancer as they did in cervical 
cancer. It had been suggested that, the presence of 
diamine oxidase and polyamine oxidase in cervical 
mucus, spermine, spermidine, and putrescine in 
the semen of male partners could contribute to the 
progression from HPV infection to cervical cancer [27, 
32, 33, 34].
 The polyamines spermine / spermidine, and 
the diamine, putrescine were oxidised by polyamine 
oxidase and diamine oxidase in the female genital tract 
(cervical mucus). Their oxidative products include 
oxygen radicals and hydrogen peroxide, acrolein, and 
reactive aldehydes which are genotoxic and may also 
have immunosuppressive effects [34].
 When assessing the association between 
vasectomy and the risk of ovarian cancer, selection 
bias and the possibility of uncontrolled confounding 
were both issues. That was because vasectomy - a 
permanent contraceptive method - was usually done 
at an older age after the completion of childbearing. 
Higher parity, use of OCs, and other factors might be 
(or might have been) more prevalent in women whose 
partners underwent vasectomy.
       It has been suggested that the inverse association 
with ovarian cancer observed with use of contraceptives 
in general could  be explained by the fact that, infertile 
women tend not to use contraceptives and were at a 
higher risk of ovarian cancer. In this case, the higher 
risk in non-users could be confounded by infertility. 
Alternatively, it could be that contraceptives had a 
relationship with ovarian carcinogenesis that was yet to 
be exploited [4].
 The reviewed studies had several limitations. 
First, in the case-control studies, there was the risk of 
misclassification of controls as they were not tested for 
the presence of asymptomatic ovarian cancer. However, 
ovarian cancer was not common and, therefore, the 
prevalence of undiagnosed ovarian cancer in controls 
would be expected to be quite low. 
 Second, in most of those studies, histology 
was not reviewed by a single pathologist and that poses 
the risk of inter-pathologist variation. There was also 
the possibility of recall bias, especially in relation to 
duration in use of specific contraceptives. As women 
often use more than one type of contraceptives, it 
was also difficult to disaggregate possible differences 
associated with the use of different contraceptives. 
 Third, the use of hospital - based controls 
had a high potential for biasness. Although, possibly 
less likelihood of recall bias given that access to 
health care could be more likely associated with 
specific forms of contraceptives. In addition, these 
were all observational studies, so there was potential 
for uncontrolled confounding by unidentified or 
unmeasured confounding factors. Furthermore, most 
of the studies had insufficient numbers of participants 
and did not report associations with long-term use.
Conclusion
 In conclusion, the association of ovarian 
cancer with use of contraceptives other than oral 
contraceptives still merits attention. For the fact that, 
the evidence it will provide to women about choices of 
contraceptive method they might make and the light it 
will cast on ovarian cancer aetiology and prevention.
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